Biodexa Pharmaceuticals Plc (BDRX) Stock Score, Valuation & Financial Research

Biodexa Pharmaceuticals Plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BDRX

Biodexa Pharmaceuticals Plc does not currently have a complete Wall Street Score. The stored market price is USD 0.60. These figures are a research snapshot, not a buy or sell recommendation.

What Biodexa Pharmaceuticals Plc does

Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Biodexa is a clinical-stage biopharmaceutical company that focuses on developing a pipeline of therapeutic assets for gastrointestinal cancers and other rare diseases. Its business model centers on advancing clinical-stage assets to proof-of-concept, after which it seeks to license these products to partners who will undertake later-stage development, marketing, and sales in exchange for milestone payments and royalties.

Products and services

  • The company's primary development pipeline includes eRapa (an oral tablet formulation of rapamycin for FAP and NMIBC), MTX240 (for GIST), and tolimidone (for Type 1 Diabetes).

Brands and product families

  • eRapa — Proprietary oral tablet formulation of rapamycin for FAP and NMIBC. Source
  • MTX240 — Clinical-stage asset for the treatment of GIST. Source
  • tolimidone — Clinical-stage asset for the treatment of Type 1 Diabetes. Source

Customer types

Pharmaceutical and biotechnology licensing partners.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company engages third-party contract manufacturers to produce clinical trial materials for its drug candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Otsuka Pharmaceutical Co., Ltd — The company licensed the asset MTX240 (formerly OPB-171775) from Otsuka in February 2026. Source
  • Cancer Prevention and Research Institute of Texas (CPRIT) — The company received $20.0 million in grant funding from CPRIT to support the development of eRapa through Phase 3 clinical trials. Source

Business strengths to evaluate

  • Clinical-stage pipeline focused on rare/orphan indications Source
  • Non-dilutive grant funding from CPRIT for eRapa development Source

Business risks and research considerations

  • Significant history of operating losses and dependence on additional capital Source
  • Risks associated with clinical trial enrollment and regulatory approval processes Source

Sources: Company research source · Otsuka Pharmaceutical Co., Ltd

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BDRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.60
Market capitalization:
444.01K (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -14.15M
Free cash flow:
USD -7.16M
Cash:
USD 4.26M
Total debt:
USD 80.78K
EPS:
USD -18.97

What stands out

  • Free cash flow is USD -7.16M, negative for the stored period.
  • The balance sheet shows USD 4.26M of cash versus USD 80.78K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.18M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BDRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BDRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BDRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BDRX to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of BDRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BDRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.